SCHEMBL4620780

SCHEMBL4620780

COC(=O)c1cc(=O)c2cc(F)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.56
NFE2L2 Q16236 1/20 0.56
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
PARP1 P09874 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
LMNA P02545 4/20 0.48
CYP1A2 P05177 1/20 0.47
FEN1 P39748 1/20 0.47
XDH P47989 2/20 0.46
GHSR Q92847 1/20 0.46
NGFR P08138 1/20 0.46
PKM P14618 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19211167 0.84 KDM4E (0.57) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL17205044 0.82 HPGD (0.56) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL11617401 0.82 ALDH1A1 (0.52) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL1503904 0.82 HPGD (0.56) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL1210328 0.82 ALDH1A1 (0.52) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL13234526 0.82 ALDH1A1 (0.61) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL9452207 0.82 KDM4E (0.57) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL9452271 0.81 NGFR (0.67) KEAP1NFE2L2GLAGAAKDM4E
SCHEMBL57291 0.80 KDM4E (0.66) GLAGAAKDM4EALDH1A1HPGD
SCHEMBL31243255 0.80 KDM4E (0.66) GLAGAAKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470708-B2 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2008-12-30 US disclosed
EP-1933811-A2 BANDED CONTROLLED RELEASE NANOPARTICLE ACTIVE AGENT FORMULATION DOSAGE FORMS AND METHODS Alza Corporation (US) 2008-06-25 EP disclosed
EP-1696924-B1 ACIDIC QUINOLINE DERIVATIVES AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF HYPERGLYCAEMIA-RELATED PATHOLOGIES MERCK PATENT GMBH (DE) 2008-03-26 EP disclosed
EP-1898885-A1 METHODS AND DOSAGE FORMS FOR REDUCING SIDE EFFECTS OF CARBAMATE COMPOUNDS Alza Corporation (US) 2008-03-19 EP disclosed
WO-2008002567-A2 METHODS OF TREATING CONDITIONS BY SUSTAINED RELEASE ADMINISTRATION OF BENZIMIDAZOLE DERIVATIVES ALZA CORPORATION (US) 2008-01-03 WO disclosed
EP-1791520-A2 CONTROLLED RELEASE NANOPARTICLE ACTIVE AGENT FORMULATION DOSAGE FORMS AND METHODS Alza Corporation (US) 2007-06-06 EP disclosed
WO-2007041079-A2 BANDED CONTROLLED RELEASE NANOPARTICLE ACTIVE AGENT FORMULATION DOSAGE FORMS AND METHODS ALZA CORPORATION (US) 2007-04-12 WO disclosed
WO-2007016388-A2 LIQUID FORMULATIONS FOR CONTROLLED DELIVERY OF BENZISOXAZOLE DERIVATIVES ALZA CORPORATION (US) 2007-02-08 WO disclosed
WO-2007002906-A1 METHODS AND DOSAGE FORMS FOR REDUCING SIDE EFFECTS OF CARBAMATE COMPOUNDS ALZA CORPORATION (US) 2007-01-04 WO disclosed
EP-1696924-A1 ACIDIC QUINOLINE DERIVATIVES AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF HYPERGLYCAEMIA-RELATED PATHOLOGIES MERCK PATENT GmbH (DE) 2006-09-06 EP disclosed
WO-2006085856-A1 METHODS AND DOSAGE FORMS FOR REDUCING SIDE EFFECTS OF BENZISOZAZOLE DERIVATIVES ALZA CORPORATION (US) 2006-08-17 WO disclosed
WO-2006069133-A2 IONIC DRUG-DETERGENT COMPLEXES ALZA CORPORATION (US) 2006-06-29 WO disclosed
WO-2006023286-A2 CONTROLLED RELEASE NANOPARTICLE ACTIVE AGENT FORMULATION DOSAGE FORMS AND METHODS ALZA CORPORATION (US) 2006-03-02 WO disclosed
WO-2005063244-A1 ACIDIC QUINOLINE DERIVATIVES AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF HYPERGLYCAEMIA-RELATED PATHOLOGIES MERCK PATENT GMBH (DE) 2005-07-14 WO disclosed
EP-1140012-A2 CONVERSION OF LIQUID FILLED GELATIN CAPSULES INTO CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS Alza Corporation (US) 2001-10-10 EP disclosed
WO-2000038650-A1 GASTRIC RETENTION DOSAGE FORM HAVING MULTIPLE LAYERS ALZA CORPORATION (US) 2000-07-06 WO disclosed
WO-2000035419-A2 CONVERSION OF LIQUID FILLED GELATIN CAPSULES INTO CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS ALZA CORPORATION (US) 2000-06-22 WO disclosed